Company: Umoja Biopharma
Job title: Senior Director - Translational Sciences
Dr. Green trained at UC Berkeley and UCSF where she developed and employed preclinical models of cancer to study tumor development and potential therapeutic approaches. She utilized these expertise to drive the preclinical development of T cell-based immunotherapies targeting both solid and liquid tumors at Eureka Therapeutics Inc. (Emeryville, CA), where she successfully guided two novel programs through preclinical proof-of-concept and safety studies to support investigational new drug applications and clinical testing. She spent two years at the Altius Institute for Biomedical Sciences (Seattle, WA) directing the development of novel genetic and epigenetic editing tools to enhance cellular therapies for cancer. Currently at Umoja Biopharma, a new startup in Seattle, she is leading the preclinical strategy to obtain proof-of-concept for potentially disruptive new approaches to cancer immunotherapy.
Roundtable: No One Size Fits All Approach – Choosing the Right Preclinical Model for the Right I/O Question 1:00 pm
day: Day Two